

Applicants: David M. Stern, et al.  
Serial No.: 09/374,213  
Filed : August 13, 1999  
Page 3

44. (New) The method of claim 41, wherein the  $\beta$ -sheet fibril is selected from the group consisting of amyloid- $\beta$  peptide, amylin, amyloid A, prion-derived peptide, transthyretin, cystatin C, gelsolin and a peptide capable of forming amyloid.

45. (new) The method of claim 44, wherein the  $\beta$ -sheet fibril is an amyloid- $\beta$  peptide is selected from the group consisting of A $\beta$  (1-39), A $\beta$  (1-40), A $\beta$  (1-42) and A $\beta$  (1-40) Dutch variant.

46. (new) The method of claim 41, wherein the compound is sRAGE or a fragment thereof.

47. (new) The method of claim 41, wherein the compound is an anti-RAGE antibody or portion thereof.

48. (new) The method of claim 47, wherein the antibody is a monoclonal antibody.

49. (new) The method of claim 48, wherein the monoclonal antibody is a human, a humanized, or a chimeric antibody.

50. (new) The method of claim 41, wherein the compound comprises a Fab fragment of an anti-RAGE antibody.

A2  
Cont.

Applicants: David M. Stern, et al.  
Serial No.: 09/374,213  
Filed : August 13, 1999  
Page 4

51.(new) The method of claim 41, wherein the compound comprises the variable domain of an anti-RAGE antibody.

52.(new) The method of claim 41, wherein the compound comprises one or more CDR portions of an anti-RAGE antibody.

53.(new) The method of claim 41, wherein the antibody is an IgG antibody.

54.(new) The method of claim 41, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 daltons.

55.(new) The method of claim 41, wherein the cell is an endothelial cell, a smooth muscle cell, a somatic cell, a bone marrow cell, a liver cell, an intestinal cell, a germ cell, a myocyte, a mononuclear phagocyte, a tumor cell, a spleen cell or a stem cell.

56.(new) The method of claim 41, wherein the compound is a peptide analog of sRAGE.

57.(new) A method of inhibiting of the binding of a  $\beta$ -sheet fibril to RAGE on the surface of a cell of a subject, wherein the cell is located outside the central nervous system of the subject, which comprises administering to the subject

enc C1  
a2  
cont.